Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

KONCERT A Kaletra ONCE Daily Randomised Trial of the Pharmacokinetics, Safety and Efficacy of Twice-daily Versus Once-daily Lopinavir/Ritonavir Tablets Dosed by Weight as Part of Combination Antiretroviral Therapy in Human Immunodeficiency Virus-1 (HIV-1) Infected Children (PENTA 18)

NCT01196195 is registered in ClinicalTrials.gov with PENTA Foundation as lead sponsor.

NCT NCT01196195
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01196195 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
KONCERT A Kaletra ONCE Daily Randomised Trial of the Pharmacokinetics, Safety and Efficacy of Twice-daily Versus Once-daily Lopinavir/Ritonavir Tablets Dosed by Weight as Part of Combination Antiretroviral Therapy in Human Immunodeficiency Virus-1 (HIV-1) Infected Children (PENTA 18)
Lead sponsor
PENTA Foundation
Phase
Phase 2/3
Overall status
Completed
Start date
August 31, 2010
Completion date
August 31, 2013
Enrollment
173 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

antiretroviral therapy in hiv-1 infected children